bioMérieux S.A. (OTCMKTS:BMXMF – Get Rating) shot up 5.1% during trading on Monday . The stock traded as high as $108.50 and last traded at $108.50. 100 shares changed hands during mid-day trading, an increase of 0% from the average session volume of 100 shares. The stock had previously closed at $103.26.
Analyst Upgrades and Downgrades
Several brokerages have commented on BMXMF. Morgan Stanley raised their target price on bioMérieux from €108.00 ($117.39) to €109.00 ($118.48) and gave the stock an “overweight” rating in a research note on Thursday, October 27th. Societe Generale upgraded bioMérieux from a “hold” rating to a “buy” rating in a research note on Wednesday, December 21st. Finally, Berenberg Bank raised their target price on bioMérieux from €89.70 ($97.50) to €92.50 ($100.54) and gave the stock a “hold” rating in a research note on Friday, December 16th.
bioMérieux Stock Performance
The firm has a fifty day simple moving average of $101.81 and a two-hundred day simple moving average of $96.19. The company has a quick ratio of 1.33, a current ratio of 2.02 and a debt-to-equity ratio of 0.10.
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors.
- Get a free copy of the StockNews.com research report on bioMérieux (BMXMF)
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Thor Industries Hammered Its Numbers. Is it a Buy?
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.